Acute myeloid leukaemia is a neoplasia in need of new treatment approaches. PARP inhibitors are a class of targeted therapeutics for cancer that disrupts dysfunctional DNA damage response in various neoplasia. MLL-AF9 mutated leukaemias are sensitive to combinations of PARP inhibitors and cytotoxic drugs. Moreover, DNMT3A and NPM1 mutations are linked to dysfunctions in DNA damage response. Therefore, we investigated if DNMT3A-NPM1 mutated AML cell line is sensible to PARP inhibitors combined with anthracyclines. Our results show that DNMT3A-NPM1 mutated AML is as sensible to combinations of PARP inhibitors and anthracyclines as MLL-AF9 mutated leukaemias, in an in vitro setting.
Acute myeloid leukaemia (AML) is a malignant disorder characterised by the accumulation of genetic aberrations in the myeloid haematopoiesis linage, that can be risk classified according to specific gene mutations (1) . Understanding the AML genome promises new therapeutic strategies that involve synthetic lethal interactions (2) . Thus, in this study we compare the effects of combining olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in malignancies bearing homologous recombination deficiencies (2) and daunorubicin (ODC) with the standard daunorubicin-cytarabine (CDR) that models the "7+3" induction regimens. Two AML cell lines were chosen: OCI/AML3 and THP-1. OCI/AML3 is characterised by a common and impactful co-occurrence of mutations in both nucleophosmin gene (NPM1), involved in DNA single strand break repairs and DNA methyltransferase 3 alpha gene (DNMT3A), involved in resistance to anthracycline-induced DNA damage (3)(4) (5) . THP-1 is characterised by mutations and deletions in PTEN, MLL-AF9, MLLT3, TP73, CDKN2A/B (6), which makes it susceptible to the effects of olaparib, particularly through the presence of a partial deletion in PTEN gene (2) .
Firstly, we subjected OCI/AML3 (DSMZ, Braunschweig, Germany) and THP1 (ATCC, Manassas, USA) cells to an in vitro drug treatment, by plating them in 96-well plates, at 10 4 cells/200µL/well in 2 types of media: 80% alpha-MEM (Invitrogen, Paisley, UK ) with 20% FBS (Invitrogen, Paisley, UK) for OCI/AML3 and RPMI1640 (Invitrogen, Paisley, UK) with 10% FBS, 2 mM L-glutamine for THP1 for 48h/72h with 37.5µM olaparib (Selleckchem, Houston, USA), 100µM cytarabine (Sigma Aldrich, Taufkirchen, Germany), 1.4µM daunorubicin (Sigma Aldrich, Taufkirchen, Germany) alone or in combination. Cells were maintained in cell culture incubators at 37°C and 5%CO2 atmosphere. Cell proliferation was assessed with the CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, USA) and analysed with a BioTek Synergy H1 Hybrid Multi-Mode Reader (BioTek Instruments, Winooski, USA). Cell cycle arrest was assessed using a flow cytometry-based approach at 48h of treatment, as described elsewhere (7) . DNA double breaks (DSB) levels after 48h and 72h treatments were determined as an increase in phosphoSer139 γH2AX foci, a DSB marker, using flow cytometry method as described elsewhere (8) . Gene expression analysis for DNA damage associated genes, ATM, RAD51, LIG3, LIG4, PARP1, PTEN and B2M, as internal normaliser, was performed using qRT-PCR as described elsewhere (9) and custom-made primers. All the experiments were conducted in triplicate and represented as means ±SEM/SD. We analysed all the data using the GraphPad Prism 6 software suite and applied ANOVA statistics and Dunnett or Sydak tests. Results were considered significant for p values ≤ 0.05.
Moving to results, ODC was as effective as CDR and daunorubicin in arresting the relative viability of the treated cells (Fig. 1A -OCI ODC and CDR treatments induced downregulations in all the evaluated genes, when compared to the untreated control, in both cell lines. For OCI/AML3, daunorubicin monotherapy did not lower expression levels more than ODC and CDR for any studied genes. However, for THP1, daunorubicin alone downregulated LIG3 and PTEN more than ODC and CDR (Fig.1 D. I) . When comparing the gene expression for OCI/AML3 cells treated with ODC relatively to the ones treated with CDR, ATM, PTEN, LIG3, LIG4 where found to be upregulated, and RAD51 and PARP1 downregulated. When the same analysis was performed for THP-1 cells, all the genes registered as downregulated (Fig 1 D. II) . Gene expression levels induced by ODC and CDR were significantly different from those generated by daunorubicin monotherapy, regardless of cell line (Dunnett's multiple comparisons test, p <0.05).
To conclude, the effects produced by ODC on blast proliferation, cell cycle and DNA damage levels mirrored the ones induced by CDR and daunorubicin regardless of the cell lines tested, but ODC generated gene expression patterns different from daunorubicin monotherapy and CDR. Our results show that NPM1-DNMT3A mutated AML is susceptible to the action of ODC in this in vitro setting and reinforce the reports that so does THP1, too (10) . This phenomenon can be attributed to increased amounts of DSB, but also probably, to the effects of ODC on the expression of RAD51 and PARP1 genes on both cell lines. This observation is intriguing since inhibition of PARP1 delays the onset of starvation and ROS-induced autophagy (11) with potential effects on blast survival. The in vitro effects of ODC on these AML cell lines suggest that combining PARP inhibitors with anthracyclines could capitalise on two defective signalling machineries in AML: DNA repair and probably, autophagy. This is of potential clinical impact, as it can ease the side effect burden of AML treatment by substituting cytarabine with olaparib in treating patients with NPM1-DNMT3A mutated AML without jeopardising efficacy.
